Affiliation:
1. Centre for Pharmaceutical Research, University of South Australia, Adelaide,1 and
2. Department of Infectious Diseases2 and
3. Pharmacy Department,3 Women's and Children's Hospital, North Adelaide, South Australia, Australia
Abstract
ABSTRACT
The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmucoid strains of
Pseudomonas aeruginosa
isolated from patients with cystic fibrosis. Twenty-three clinical strains, including multiresistant strains, and one type strain were selected for MIC determination. Eleven strains were resistant; MICs for these strains were >128 mg/liter. For the susceptible strains, MICs of colistin ranged from 1 to 4 mg/liter, while the MICs of colistin methanesulfonate were significantly higher and ranged from 4 to 16 mg/liter. The time-kill kinetics were investigated with three strains at drug concentrations ranging from 0.5 to 64 times the MIC. Colistin showed extremely rapid killing, resulting in complete elimination at the highest concentrations within 5 min, while colistin methanesulfonate killed more slowly, requiring a concentration of 16 times the MIC to achieve complete killing within 24 h. Colistin exhibited a significant PAE of 2 to 3 h at 16 times the MIC against the three strains after 15 min of exposure. For colistin methanesulfonate, PAEs were shorter at the concentrations tested. Colistin methanesulfonate had lower overall bactericidal and postantibiotic activities than colistin, even when adjusted for differences in MICs. Our data suggest that doses of colistin methanesulfonate higher than the recommended 2 to 3 mg/kg of body weight every 12 h may be required for the effective treatment of
P. aeruginosa
infections in cystic fibrosis patients.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference16 articles.
1. Anonymous
Colistin
The Merck index
12th ed.
Budavari
S.
O'Neil
M. J.
Smith
A.
Heckelman
P. E.
Kinnearny
J. F.
1996
419
420
Merck & Co.
Whitehouse Station N.J
2. Intravenous administration of sodium colistimethate.;Baines R. D.;JAMA,1964
3. A reassessment of the in vitro activity of colistin sulphomethate sodium.;Catchpole C. R.;J. Antimicrob. Chemother.,1997
4. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.;Conway S. P.;Thorax,1997
5. Craig
W. A.
Gudmundsson
S.
Postantibiotic effect
Antibiotics in laboratory medicine
3rd ed.
Lorian
V.
1991
403
431
Williams and Wilkins
Baltimore Md
Cited by
212 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献